Here are four observations:
1. Biologics’ popularity among spine surgeons will drive the market, along with the minimally invasive nature of the procedure and a growing geriatric population.
2. Currently, North America holds the largest market share, with Europe coming in second, due to advanced technologies and high per capita income.
3. The Asian-Pacific market is set to grow at a high rate because of an increasing population, better medical coverage and growing demand in India and China.
4. Key market players include Alphatec Spine, DePuy Synthes, Medtronic, Stryker, Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.
More articles on devices:
Conventus Orthopaedics names new CEO — 4 things to know
Mazor Robotics, Stryker, K2M & more: 19 device company key notes
Vertebral compression fracture devices market to reach $1.1M by 2022: 5 insights
